CARE Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Careium AB (publ) - Alpha Spread
C

Careium AB (publ)
STO:CARE

Watchlist Manager
Careium AB (publ)
STO:CARE
Watchlist
Price: 32.8 SEK -1.5% Market Closed
Market Cap: 797.9m SEK
Have any thoughts about
Careium AB (publ)?
Write Note
Section:
 
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CARE Price Targets Summary
Careium AB (publ)

Wall Street analysts forecast CARE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CARE is 25 SEK .

CARE Lowest Forecast
Wall Street Target
Not Available
CARE Average Forecast
Wall Street Target
25 SEK
24% Downside
CARE Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
25 SEK
24% Downside
Highest
Price Target
Not Available
Careium AB (publ) Competitors:
Price Targets
A
688617
APT Medical Inc
4% Upside
MEDI
Medistim ASA
7% Upside
I
ITGR
Integer Holdings Corp
1% Upside
INMD
Inmode Ltd
21% Upside
A
688617
APT Medical Inc
4% Upside
MEDI
Medistim ASA
7% Upside
I
ITGR
Integer Holdings Corp
1% Upside
INMD
Inmode Ltd
21% Upside
2160
Microport Cardioflow Medtech Corp
266% Upside
PDEX
Pro-Dex Inc
8% Upside
IMR
Imricor Medical Systems Inc
83% Upside
AXNX
Axonics Inc
6% Upside

Revenue
Forecast

Revenue Estimate
Careium AB (publ)

For the last 2 years the compound annual growth rate for Careium AB (publ)'s revenue is 18%. The projected CAGR for the next 3 years is 11%.

18%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Careium AB (publ)

For the last 2 years the compound annual growth rate for Careium AB (publ)'s operating income is 163%. The projected CAGR for the next 3 years is 23%.

163%
Past Growth
23%
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Careium AB (publ)

For the last 2 years the compound annual growth rate for Careium AB (publ)'s net income is 195%. The projected CAGR for the next 3 years is 27%.

195%
Past Growth
27%
Estimated Growth
Estimates Accuracy
-46%
Average Miss
What are analyst estimates?

See Also

Summary
CARE intrinsic value, competitors valuation, and company profile.
DCF Valuation
CARE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CARE stock valuation using valuation multiples.
Wall Street Estimates
CARE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CARE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CARE's stock price target?
Price Target
25 SEK

According to Wall Street analysts, the average 1-year price target for CARE is 25 SEK .

What is Careium AB (publ)'s Revenue forecast?
Projected CAGR
11%

For the last 2 years the compound annual growth rate for Careium AB (publ)'s revenue is 18%. The projected CAGR for the next 3 years is 11%.

What is Careium AB (publ)'s Operating Income forecast?
Projected CAGR
23%

For the last 2 years the compound annual growth rate for Careium AB (publ)'s operating income is 163%. The projected CAGR for the next 3 years is 23%.

What is Careium AB (publ)'s Net Income forecast?
Projected CAGR
27%

For the last 2 years the compound annual growth rate for Careium AB (publ)'s net income is 195%. The projected CAGR for the next 3 years is 27%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 179,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.